Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age

BACKGROUND: IMPAACT P1066 is a Phase I/II open-label multicenter trial to evaluate safety, tolerability, pharmacokinetics (PK), and efficacy of multiple raltegravir (RAL) formulations in human immunodeficiency virus (HIV)-infected youth. METHODS: Dose selection of the oral suspension formulation for...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Pediatric Infect Dis Soc
Hauptverfasser: Nachman, Sharon, Alvero, Carmelita, Acosta, Edward P., Teppler, Hedy, Homony, Brenda, Graham, Bobbie, Fenton, Terence, Xu, Xia, Rizk, Matthew L., Spector, Stephen A., Frenkel, Lisa M., Worrell, Carol, Handelsman, Edward, Wiznia, Andrew
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2015
Schlagworte:
ELECTRONIC ARTICLES
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4681385/
https://ncbi.nlm.nih.gov/pubmed/26582887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jpids/piu146
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge